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Abstract: In the central nervous system, cystine import in exchange for
glutamate through system xc− is critical for the production of the antioxidant
glutathione by astrocytes, as well as the maintenance of extracellular
glutamate. Therefore, regulation of system xc− activity affects multiple
aspects of cellular physiology and may contribute to disease states. Pituitary
adenylate cyclase-activating polypeptide (PACAP) is a neuronally-derived
peptide that has already been demonstrated to modulate multiple aspects of
glutamate signaling suggesting PACAP may also target activity of cystineglutamate exchange via system xc−. In the current study, 24-hour treatment
of primary cortical cultures containing neurons and glia with PACAP
concentration-dependently increased system xc− function as measured by
radiolabeled cystine uptake. Furthermore, the increase in cystine uptake was
completely abolished by the system xc− inhibitor, (S)-4-carboxyphenylglycine
(CPG), attributing increases in cystine uptake specifically to system x c−
activity. Time course and quantitative PCR results indicate that PACAP
signaling may increase cystine-glutamate exchange by increasing expression
of xCT, the catalytic subunit of system xc−. Furthermore, the potentiation of
system xc− activity by PACAP occurs via a PKA-dependent pathway that is not
mediated by the PAC1R, but rather the shared vasoactive intestinal
polypeptide receptor VPAC1R. Finally, assessment of neuronal, astrocytic, and
microglial-enriched cultures demonstrated that only astrocyte-enriched
cultures exhibit enhanced cystine uptake following both PACAP and VIP
treatment. These data introduce a novel mechanism by which both PACAP
and VIP regulate system xc− activity.

Keywords: PACAP, VIP, system xc−, astrocyte
1. Introduction
In the central nervous system (CNS) cystine-glutamate exchange is
critical for the maintenance of extracellular glutamate concentrations
(Baker et al., 2002; Moran et al., 2005; Murphy and Baraban, 1990),
as well as supplying cystine to astrocytes for glutathione production
(Kranich et al., 1998; Sagara et al., 1993). The cystine-glutamate
antiporter, system xc−, composed of the light chain xCT and heavy
chain 4F2hc subunits, is a sodium independent amino acid transporter
that exchanges one molecule of extracellular cystine for one molecule
of intracellular glutamate (Bannai, 1986; Bannai and Kitamura, 1980;
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Sato et al., 1999). Nonvesicular extrasynaptic glutamate release by
system xc− expressed on astrocytes may be important for activation of
extrasynaptic NMDA and group II/III metabotropic glutamate
receptors that, in turn, affect neuronal excitability (Kupchik et al.,
2012; Moran et al., 2005; Pow, 2001). In support, nonvesicular
glutamate released by the cystine-glutamate antiporter is reported to
be an essential regulator of extrasynaptic glutamate concentrations in
the CNS (Baker et al., 2002). Moreover, dysregulation of extrasynaptic
glutamate concentrations resulting from altered system xc− activity has
been implicated in glutamate excitotoxicity (Piani and Fontana, 1994)
and psychiatric disorders (Baker et al., 2008; Baker et al., 2003). With
the large array of pathological states in the CNS stemming from both
insufficient glutathione synthesis and dysfunctional glutamate
homeostasis, system xc− is positioned to heavily influence a variety of
pathologies ranging from compulsive disorders to neurodegenerative
disease (Berman et al., 2011; de Groot and Sontheimer, 2011; Grant
et al., 2007; Grant et al., 2009; Knackstedt et al., 2009; Park et al.,
2004; Sontheimer, 2011; Zhou and Kalivas, 2008). Unfortunately, the
regulation of this heterodimeric amino acid transporter is poorly
understood.
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a
pleiotropic neuropeptide with widespread expression throughout the
central nervous system (CNS) and periphery (Ghatei et al., 1993;
Hannibal, 2002; Vaudry et al., 2009). In the CNS, substantial evidence
has linked PACAP signaling to glutamate neurotransmission through its
modulation of the ionotropic glutamate receptors NMDA and AMPA
(Chen et al., 1999; Costa et al., 2009; Macdonald et al., 2005; Yaka et
al., 2003). Furthermore, all PACAP receptors, including the high
affinity PAC1 receptor as well as the vasoactive intestinal polypeptide
(VIP) receptors VPAC1 and VPAC2, are reportedly expressed on
astrocytes (Ashur-Fabian et al., 1997; Grimaldi and Cavallaro, 1999;
Grimaldi and Cavallaro, 2000; Masmoudi-Kouki et al., 2007; Suzuki et
al., 2003; Tatsuno et al., 1991) suggesting a significant involvement of
PACAP signaling in the regulation of astrocyte function. This notion is
further supported by PACAP treatment of primary astrocyte cultures
producing increased expression and function of the glial glutamate
transporters GLT-1 and GLAST (Figiel and Engele, 2000), which are
needed for clearance of vesicular glutamate released by neurons from
the synapse in order to prevent spillover of synaptic glutamate into
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extrasynaptic areas (Asztely et al., 1997; Diamond and Jahr, 2000;
Zheng et al., 2008). Importantly, PACAP synthesis and transmission
may be exclusively released from glutamate neurons in the CNS
(Fahrenkrug and Hannibal, 2004; Hannibal et al., 2000) allowing
PACAP to have a potential modulatory role on glutamate signaling at
both the neuron as well as on the surrounding glia.
While PACAP appears to be a critical signal for astrocytes
(Masmoudi-Kouki et al., 2007), as well as a key modulator of
glutamate signaling (Magistretti et al., 1998), the affects of PACAP
signaling on system xc− function are unknown. To test whether PACAP
may regulate the activity of the cystine-glutamate antiporter we
performed radiolabeled cystine uptake assays in primary cortical
cultures following PACAP treatment. System xc− activity was
potentiated following 24-hour treatment with PACAP and subsequent
experiments were performed to determine the specific mechanism
mediating the increased cystine-glutamate exchange produced by
PACAP application in these cultures.

2. Materials and Methods
2.1 Materials
Timed pregnant female Swiss Webster mice (Charles River
Laboratories; Wilmington, DE) were housed in a climate-controlled
room with a 12 hr light/dark cycle. Animals had free access to
standard diet (Harlan 8604 formulation) and water until preparation of
cell cultures. All procedures using animals were approved by the
Marquette University Institutional Animal Care and Use Committee.
PACAP was obtained from California Peptide Research (Napa, CA),
PACAP6-38 from Anaspec (Fremont, CA), and VIP, VIP6-28, PG 97269, PG 99-465 from Bachem (Torrance, CA). (S)-4carboxyphenyglycine (CPG) was purchased from Tocris Bioscience
(R&D Systems; Minneapolis, MN), and H89 from Sigma (St. Louis,
MO). All other common chemicals were purchased from Sigma (St.
Louis, MO).
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2.2 Cortical cell cultures
Primary mixed cortical cultures containing both neurons and glia
were prepared from embryonic day 15–16 mouse pups as previously
described (Lobner, 2000). Dissociated cortical cells suspended in
Eagles’ Minimal Essential Medium (MEM, Earle’s salts, supplied
glutamine-free) supplemented with 5% heat-inactivated horse serum
(Atlanta Biologicals; Lawrenceville, GA), 5% fetal bovine serum
(Atlanta Biologicals), 2 mM glutamine and glucose (total 21 mM) were
plated on 24-well plates coated with poly-D-lysine and laminin.
Neuronal-enriched cultures were prepared in an identical manner with
the addition of 10 µM cytosine arabinoside 48 hours after plating
cultures in order to inhibit glial replication. Neuronal-enriched cultures
using this method have astrocyte levels of <1% of the total cell
population (Dugan et al., 1995; Rush et al., 2010). Astrocyte-enriched
glial cultures were prepared using a similar protocol to that of the
mixed cortical culture, however cortices were obtained from postnatal
day 1–3 mouse pups (Choi et al., 1987; Rush et al., 2010; Schwartz
and Wilson, 1992). To obtain microglial cultures, microglia were
collected after shaking astrocyte-enriched glial cultures and then
plated in media containing 10 ng/ml colony stimulating factor (CSF)
(Barger and Basile, 2001). All cultures were maintained in humidified
5% CO2 incubators at 37°C.

2.3 Radiolabeled cystine uptake
Radiolabeled cystine uptake was measured as previously
described (Liu et al., 2014; Liu et al., 2012; Liu et al., 2009; Rush et
al., 2012). Briefly, prior to treatment on in vitro day 15, cultures were
washed in serum-free media and incubated for a specified period with
or without drug. Following incubation, cultures were then washed with
HEPES buffered saline solution and immediately exposed to 0.3 µM
14
C-cystine (Perkin Elmer; Waltham, MA) for 20 minutes. This
concentration of 14C-cystine was used in order to simulate the
estimated level of extracellular cystine found in the brain (Baker et al.,
2003). Following 14C-cystine exposure the cultures were washed with
HEPES buffered saline solution and dissolved in 250 µl of 0.1% sodium
dodecyl sulfate. Of the 250 µl sample, 200 µl were used for
scintillation counting, with the remaining sample used for protein
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quantification using the Bio-Rad DC protein assay (Hercules, CA).
Counts were normalized protein concentration in each well and
expressed as a percentage of 14C-cystine uptake in controls on the
same experimental plate. For experiments using CPG, 200 µM CPG was
added to the 14C-cystine solution during the 20 minute uptake
experiment.

2.4 Quantitative reverse transcription PCR
Cultures used for qRT-PCR were treated the same as for
radiolabeled cystine uptake assays. However, following drug
incubation, cells were harvested for total RNA extraction using TRiZOL
(Life Technologies; Grand Island, NY). Single-stranded cDNA synthesis
was performed with 1 µg total RNA using the Promega Reverse
Transcription System (Madison, WI). Real-time quantitative PCR was
performed with the StepOne real-time PCR system (Applied
Biosystems; Carlsbad, CA) using PerfeCTa SYBR Green FastMix
containing ROX (Quanta Biosciences; Gaithersberg, MD). Relative
quantification of xCT transcripts was analyzed via the ∆∆Ct method
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Primers for each gene were designed to span an exon-exon junction
and had efficiencies of approximately 95%. Product sizes for each
primer set were 88 bp for xCT and 116 bp for GAPDH. Melt curve
analysis of experiments confirmed a single product for each reaction.
Primer sequences were as follows: xCT forward – AGG GCA TAC TCC
AGA ACA CG; xCT reverse – GAC AGG GCT CCA AAA AGT GA; GAPDH
forward – AAG GGC TCA TGA CCA CAG TC; and GAPDH reverse – GGA
TGC AGG GAT GAT GTT CT.

2.5 Statistics
Data are presented as means ± standard errors of the mean, and were
analyzed statistically by analysis of variance. Fischer LSD analysis was
used for all post-hoc group comparisons. Statistical analyses were
performed using Sigma Plot 11 software (Systat Software Inc.; San
Jose, CA). P < 0.05 were considered statistically significant.
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3. Results
The effect of PACAP on system xc− activity was initially tested in
primary mixed cortical cultures following 24-hour treatment of PACAP
using concentrations ranging from 0.01 to 10 nM. Radiolabeled cystine
uptake was significantly increased only at a concentration of 1 nM
PACAP (Fig. 1A; P < 0.01). Consequently, we used the 1 nM
concentration of PACAP for all future experiments examining cystine
uptake following PACAP treatment unless otherwise stated. To
determine whether the increased cystine uptake induced by PACAP
could be attributed completely to increased system xc− activity, we coapplied the system xc− inhibitor CPG (200 µM) with the radiolabeled
cystine during uptake experiments, as the use of CPG for inhibition of
system xc− has been used previously in a similar manner without
negatively affecting cell viability (Fogal et al., 2007; Liu et al., 2014;
Liu et al., 2012). CPG inhibited approximately 90% of radiolabeled
cystine uptake in control cells as well as the increase in system xc−
activity following 24-hour PACAP treatment (Fig. 1B; P < 0.05).

Figure 1. PACAP increases cystine uptake through system xc− in a concentration-

dependent manner. (A) Concentration response of 24-hour PACAP treatment on
primary mixed cortical cultures on radiolabeled cystine uptake (n = 6–12). (B)
Inhibition of system xc− with (S)-4-carboxyphenylglycine (CPG; 200 µM) blocks cystine
uptake in both control and PACAP (1 nM) treated primary mixed cortical cultures (n =
4–12). Data are expressed as mean ± SEM. * = P < 0.05 compared to control group.

To determine the optimal incubation period for PACAP treatment
needed to augment system xc− activity, mixed cortical cultures were
incubated with 1 nM PACAP for 1, 3, 6, 12, and 24 hours prior to the
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radiolabeled cystine uptake assay. PACAP treatment produced
significant increases in cystine uptake following incubation times
ranging from 6–24 hours (Fig 2A; P < 0.05). The necessity for longterm treatment with PACAP to significantly increase cystine uptake in
primary mixed cortical cultures suggests that PACAP may be involved
with the transcriptional regulation of the cystine-glutamate antiporter.
Using quantitative real-time PCR (qPCR) we measured mRNA
expression of the catalytic subunit of system xc−, xCT. Relative
quantification for xCT mRNA was performed on total RNA extracted
from control or PACAP-treated primary mixed cortical cultures for 24
hours normalized to the housekeeping gene GAPDH. PACAP treatment
for 24 hours produced significantly increased xCT mRNA levels in these
cultures (Fig. 2B; P < 0.01).

Figure 2. Time course of cystine uptake and quantitative PCR for xCT mRNA
expression following PACAP treatment. (A) A time course revealed a delayed effect of
PACAP (1nM) on cystine uptake in primary mixed cortical cultures. PACAP treatment
for 6, 12, and 24 hours yielded significant increases in radiolabeled cystine uptake (n
= 6–8). (B) Quantitative PCR from RNA isolated from control and 24-hour PACAP (1
nM) treated primary mixed cortical cultures (n = 7–8). Data are expressed as mean ±
SEM. * = P < 0.05 compared to control group.

PACAP signaling through its G protein-coupled receptors often
utilizes Gαs to increase adenylyl cyclase, a process leading to cyclic
AMP formation and increased activation of protein kinase A (PKA)
(Dickson and Finlayson, 2009). To determine whether the PKA
pathway contributed to augmented system xc− activity by PACAP,
mixed cortical cultures were treated with 10 µM H89 (Figiel and
Engele, 2000), a PKA inhibitor, during the 24-hour PACAP treatment.
Inhibition of PKA activity by H89 completely blocked the increase in
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radiolabeled cystine uptake induced by PACAP treatment (Fig. 3; P <
0.05).

Figure 3. PACAP increases cystine uptake via a PKA-dependent pathway. 10 µM of
the PKA inhibitor H89 completely blocked increases in cystine uptake induced by 24hour PACAP (1 nM) treatment in primary mixed cortical cultures (n = 8–16). Data are
expressed as mean ± SEM. * = P < 0.05 compared to control group.

To identify the PACAP receptor type mediating the effects on
cystine-glutamate exchange, cortical cultures were co-incubated with
antagonists for the PAC1 receptor or VPAC receptors. Inhibition of the
PAC1 receptor with 100 nM PACAP6-38 did not block PACAP facilitated
radiolabeled cystine uptake, but instead potentiated the effects of
PACAP treatment alone (Fig 4A; P < 0.05 compared to PACAP
treatment). The nonspecific VPAC receptor antagonist VIP6-28 at a
concentration of 100 nM was effective in attenuating the increased
cystine uptake following 24 hour 1 nM PACAP treatment (Fig. 4B; P <
0.05). To further investigate which VPAC receptors were involved in
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the augmentation of system xc− activity, primary mixed cortical
cultures were pre-treated with specific antagonists for VPAC1R and
VPAC2R. A 100 nM concentration of the VPAC1R antagonist PG 97-269
blocked the increased cystine uptake produced by 24 hour PACAP (1
nM) treatment in mixed cortical cells (Fig. 4C; P < 0.05), while similar
treatment with the VPAC2R antagonist PG 99-465 had no effect (Fig.
4D; P < 0.05). Finally, a concentration response using VIP
concentrations ranging from 1, 10, and 100 nM also produced
significant increases in radiolabeled cystine uptake (Fig. 4E; P < 0.05).
To isolate which cell type in a mixed cortical culture preparation
primarily contributed to the increased radiolabeled cystine uptake
following incubation with PACAP or VIP, we performed similar assays
using neuronal, astrocyte, and microglia-enriched cultures. Optimal
concentrations determined from previous concentration response
experiments in mixed cortical cultures resulted in the use of 1 nM
PACAP (Fig. 1A) and 10 nM VIP (Fig. 4E) concentrations to test cell
type specific effects on cystine uptake. Incubation with either PACAP or
VIP produced significant increases in radiolabeled cystine uptake in
astrocyte-enriched cultures only (Fig. 5B; P < 0.01), with no changes
detected in neuronal or microglia-enriched cultures. Furthermore,
vehicle treatment of astrocyte-enriched glial cultures exhibited much
higher radiolabeled cystine uptake (6.48 ± 0.33 cpm/µg protein)
compared to vehicle treated neuronal (1.54 ± 0.07 cpm/µg protein)
and microglial-enriched (2.45 ± 0.30 cpm/µg protein) cultures.
Increased concentrations of PACAP (10 nM) and VIP (100 nM) included
in astrocyte-enriched culture experiments from Figure 5B also
produced significantly increased cystine uptake (Fig. 6; P < 0.05).
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Figure 4. Increases in cystine uptake induced by PACAP are mediated by the
VPAC1R. (A) The PAC1R antagonist PACAP6-38 (100 nM) caused a potentiation of 1
nM PACAP on cystine uptake (n = 16–24). (B) The VIP receptor antagonist VIP6-28
(100 nM) significantly attenuated the increased cystine uptake caused by PACAP
treatment (n = 7–16). (C) Treatment with 100 nM PG 97-269 (specific VPAC1R
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antagonist) abolished the 1 nM PACAP effect on cystine uptake (n = 8–16), while (D)
100 nM PG 99-465 (VPAC2R antagonist) had no effect (n = 8–12). (E) A concentration
response of 24-hour VIP treatment showed that VIP increases cystine uptake at a
similar concentration to PACAP, as well as at the higher concentration ranges where
PACAP was ineffective (n = 8–16). Data are expressed as mean ± SEM. * = P < 0.05
compared to control group. # = P < 0.05 compared to PACAP group.

Figure 5. Cell type specific analysis of PACAP and VIP treatment on cystine uptake.
(A) Cystine uptake was unaffected following PACAP (1 nM) and VIP (10 nM) treatment
in neuronally-enriched cultures (n = 6–16). (B) Both PACAP and VIP significantly
increased cystine uptake in astrocyte-enriched cultures (n = 8–16). (C) There was no
affect of PACAP or VIP on microglial cystine uptake (n = 5–8). Data are expressed as
mean ± SEM. * = P < 0.05 compared to control group.

Figure 6. Cystine uptake in astrocyte-enriched glial cultures following treatment with
increased concentrations of PACAP and VIP. In contrast to mixed cortical cultures,
radiolabeled cystine uptake in astrocyte-enriched glial cultures was increased by both
1 and 10 nM PACAP, while VIP treatment again showed significantly increased uptake
at both 10 and 100 nM similar to mixed culture treatment (n = 6–16). Data are
expressed as mean ± SEM. * = P < 0.05 compared to control group.
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4. Discussion
Previous reports have indicated that both neuropeptides and
growth factors may be potential regulators of the cystine-glutamate
antiporter, system xc− (Johnson and Johnson, 1993; Liu et al., 2012).
The present study demonstrates that the pleiotropic neuropeptide
PACAP is a novel regulator of system xc− activity. PACAP treatment of
primary mixed cortical cultures in vitro for 24 hours significantly
increased radiolabeled cystine uptake. Inhibition of system xc− via coadministration of CPG with radiolabeled cystine eliminated cystine
uptake almost completely in both control and PACAP-treated cultures
indicating that PACAP facilitated cystine uptake was mediated
specifically through system xc−. Furthermore, the increases in cystineglutamate exchange appear to be mediated, in part, by increased
transcription of the specific light chain subunit of system xc−, xCT. This
induction of cystine-glutamate exchange activity appears to be driven
primarily via VPAC1R signaling through a PKA-dependent pathway that
is specific to astrocytes in our primary cortical cultures.
A concentration-response of PACAP treatment on primary mixed
cortical cultures for 24 hours produced a unique response curve of
cystine uptake with a significant increase at the optimal concentration
of 1 nM, while a concentration of 10 nM PACAP did not produce any
changes in cystine uptake (Fig. 1A). Of note, PACAP treatment can
produce proliferation of astrocytes in vitro and a similar bell-shaped
response curve was reported in these experiments (Hashimoto et al.,
2003; Tatsuno et al., 1996), however, our data involving radiolabeled
cystine uptake was normalized to total protein concentration in each
well therefore accounting for any changes in astrocyte populations. In
addition, the increase in cystine uptake in primary mixed cortical
cultures at 1 nM PACAP was relatively modest compared to increases
observed in astrocyte-enriched glial cultures that possess both
astrocytes and microglia and lack neurons (Fig. 5B) suggesting that
PACAP-mediated regulation of system xc− is primarily driven by
signaling on astrocytes. In support, the use of microglial cultures
showed no significant increases in cystine uptake from either PACAP or
VIP treatment (Fig. 5C) ruling out significant contributions of microglia
within the astrocyte-enriched cultures. Interestingly, large increases in
cystine uptake were observed at the 10 nM concentration of PACAP in
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astrocyte-enriched cultures (Fig. 6), which did not occur in mixed
cultures indicating that PACAP stimulation of neurons may evoke
release of other factors capable of affecting cystine-glutamate
exchange via system xc− on astrocytes.
Effects produced by PACAP signaling are often attributed to
PAC1R activation including the enhancement of glial sodium-dependent
excitatory amino acid transporters (EAAT) following PACAP treatment
of astrocyte cultures (Figiel and Engele, 2000), however, in our studies
the PAC1R antagonist PACAP6-38 actually potentiated the effect of 1
nM PACAP treatment in mixed cultures on cystine uptake (Fig. 4A).
Instead, the nonspecific VIP receptor antagonist VIP6-28 and the
VPAC1R antagonist PG 97-269 both blocked PACAP-induced increases
in cystine uptake suggesting that regulation of system xc− in mixed
cortical cells is achieved through VPAC1R signaling. Furthermore, a
concentration-response of VIP treatment did not produce the same
response profile for cystine uptake in primary mixed cortical cultures
as PACAP (Fig. 4E), indicating that VIP-neuron interactions do not
suppress system xc− activity, and because VIP does not bind to PAC1R,
perhaps demonstrating a role for neuronal PAC1R activation in
reducing cystine-glutamate exchange during prolonged treatments in
vitro.
PACAP and VIP are neurotrophic peptides that have numerous
effects on both astrocyte function and glutamate homeostasis
(Arimura et al., 1994; Brenneman et al., 1998; Figiel and Engele,
2000; Hannibal et al., 2000; Magistretti et al., 1998; Martin et al.,
1995; Masmoudi-Kouki et al., 2011; Morio et al., 1996; Seaborn et al.,
2011; Yuhara et al., 2001). As an excitatory neuropeptide expressed
in glutamatergic neurons, PACAP enhances both NMDA and AMPA
currents in the hippocampus through PAC1R signaling (Costa et al.,
2009; Hannibal et al., 2000; Macdonald et al., 2005; Yaka et al.,
2003). In addition, VIP and PACAP also convey signals of metabolic
need to astrocytes by induction of glycogenolysis (Magistretti et al.,
1998). Thus, regulation of cystine-glutamate exchange activity is yet
another mechanism by which PACAP and/or VIP can modulate
glutamate signaling through control of astrocyte function. Considering
PACAP and VIP ameliorate glutamate toxicity and oxidative stress
(Brown, 2000; Masmoudi-Kouki et al., 2011; Morio et al., 1996; Said
et al., 1998; Shintani et al., 2005; Vaudry et al., 2002), their signaling
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may act through augmenting system xc− activity in order to increase
extrasynaptic glutamatergic tone on the presynaptic group II/III
metabotropic glutamate autoreceptors, dampening the potentially
harmful excessive synaptic release of neurotransmitter.
Primary cortical neurons express PAC1 and VPAC2 receptor
subtypes, while primary cortical astrocytes express all three receptor
subtypes including VPAC1 (Grimaldi and Cavallaro, 1999). It is still
unclear how treatment with PACAP for periods of 24 hours or more
affects PACAP receptor signaling and expression, however, in the
current experiments augmented system xc− activity occurs via
activation of the VPAC1 receptor after six or more hours of treatment.
In vivo expression of the VPAC1R is distributed throughout the central
nervous system of rodents, with very high levels of immunoreactivity
reported in cortical layers (Joo et al., 2004). Notably, aged rats display
decreased VPAC1R expression in cortex, hippocampus, and amygdala
(Joo et al., 2005), and coincidentally these same brain regions are also
areas that are high risk for neurodegeneration, which can contribute to
cognitive decline. Glutathione availability has also been shown to
decline with age, and is thought to underlie the development of
disease due to oxidative stress (Liu et al., 2004; Suh et al., 2004).
Therefore, one contributing factor to the decline of glutathione
production and increased incidence of cognitive decline with age may
be the decreased expression of VPAC1R causing less cystine-glutamate
exchange in the cognitive centers of the brain.
Alterations in system xc− activity and expression have been
implicated in various disease states such as gliomas, schizophrenia,
and drug abuse (Baker et al., 2008; Baker et al., 2003; Ye et al.,
1999). Oxidative stress and glutamate dysfunction lead to the
development of numerous pathologies, demonstrating that system xc−
may be an attractive target for drug development. However, it should
be noted that conflicting evidence exists regarding the phenotype of
xCT knockout mice, where spontaneous deletion of the xCT gene
characterized in sut/sut mutant mice results in significant brain
atrophy (Shih et al., 2006), the genetically engineered xCT knockout
mice do not appear to have significant behavioral or morphological
deficits (Lewerenz et al., 2013). Furthermore, increased system xc−
activity may produce excitotoxicity under certain circumstances such
as in primary brain tumors (de Groot and Sontheimer, 2011),
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interleukin-1β mediated hypoxic neuronal injury (Fogal et al., 2007;
Jackman et al., 2010), and long-term treatment with fibroblast growth
factor-2 (FGF-2) in vitro (Liu et al., 2014).
The current study identifies a novel neuropeptide signal that
regulates the function of the cystine-glutamate antiporter. PACAP/VIP
signaling may critically modulate system xc− activity throughout the
CNS conveying signals to astrocytes of increased activity and oxidative
stress at the synapse. Future studies are needed to examine the
potentially harmful affects of abnormal PACAP/VIP signaling on system
xc− function, as well as the therapeutic potential of targeting these
neuropeptides in order to drive system xc− activity for the treatment of
disease.
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